Q1 2026 biopharma therapeutic and platform M&A shifted toward fewer, larger, and higher-quality acquisitions, with buyers prioritizing late-stage, commercially validated, and strategically differentiated assets. Biopharma Therapeutics and Platform M&A recorded 25 deals worth $49.7B, including contingents, versus 33 deals worth $46.8B in Q4 2025. Cash value excluding contingents reached $40.8B, while average upfront cash and equity increased to $2.6B from $2.1B, and median deal value rose to $1.8B from $750M.
Biopharma Therapeutics and Platform M&A by Top Modalities in Q1 2026 was led by Small Molecule with 14 deals worth $25B, followed by Biologics, Antibody, DNA, RNA, Protein, etc. at $13.9B, and Cell Therapy at $8.2B from only 3 deals, highlighting concentration in large strategic transactions.
Biopharma Therapeutics and Platform M&A by Top Therapy Areas in Q1 2026 was dominated by Cancer with $21.5B across 7 deals, followed by Neurologic at $10.3B across 5 deals. Ophthalmic generated the highest per-deal value at $6.1B from a single transaction. Top Deals included Gilead acquiring Arcellx for an implied equity value of $8.2B, Eli Lilly acquiring Centessa Pharmaceuticals for approximately $6.3B upfront plus up to $1.5B in CVRs, Merck acquiring Terns Pharmaceuticals for $6.7B, Biogen acquiring Apellis Pharmaceuticals for $6.1B, and Novartis acquiring Pikavation Therapeutics in a deal worth up to $3B.
In Q1 2026, biopharma therapeutic and platform M&A activity remained robust, with 25 deals generating $49.7B in total transaction value, including contingents, slightly above the $46.8B recorded across 33 deals in Q4 2025. While deal volume declined quarter over quarter, higher aggregate value reflected a shift toward larger-scale transactions. Cash value excluding contingents totaled $40.8B versus $43.8B in Q4 2025, but average upfront cash and equity consideration increased to $2.6B from $2.1B, while median deal value rose sharply to $1.8B from $750M. Combined two quarters delivered 58 deals worth $96.5B, including $84.6B in cash excluding contingents.
Biopharma Therapeutics and Platform M&A by Top Modalities – Q1 2026
In Q1 2026, Small Molecule led biopharma therapeutic and platform M&A activity by both deal volume and total value, with 14 deals generating $25B, including contingents, and $20.9B excluding contingents. Biologics, Antibody, DNA, RNA, Protein, etc., followed with 10 deals worth $13.9B, including $12.1B in cash value excluding contingents, and demonstrated stronger upfront economics than Small Molecule, with average upfront cash and equity of $2.4B and a median of $1.9B. Cell Therapy recorded only 3 deals but delivered $8.2B in total value and $7.8B in cash value, excluding contingents, with both average and median upfront cash and equity at $7.8B. Immunotherapy accounted for 2 deals valued at $2.4B, including contingents and no cash value. Overall, the leading modalities generated 29 deals worth $49.6B, including $40.8B in cash value excluding contingents, with transaction value concentrated primarily in Small Molecule, Biologics, and Cell Therapy.
Â
Biopharma Therapeutics and Platform M&A by Top Therapy Areas – Q1 2026
In Q1 2026, Cancer led biopharma therapeutic and platform M&A activity by both deal volume and total value, with 7 deals generating $21.5B, including contingents, and $19.3B excluding contingents. Neurologic ranked second with 5 deals valued at $10.3B, including $8.2B in cash value excluding contingents, supported by strong average upfront cash and equity of $2.7B. Ophthalmic recorded only 1 deal but delivered a notable $6.1B in total value and $5.6B excluding contingents, representing the highest upfront value on a per-deal basis. Autoimmune and Inflammation each accounted for 3 deals, valued at $4.7B and $4.5B, respectively, although Inflammation generated stronger cash value excluding contingents at $4B compared with $1.7B for Autoimmune. Cardiovascular and Infectious contributed modestly, with 2 deals worth $1.1B and 1 deal worth $900M, respectively. Overall, leading therapy areas recorded 22 deals worth $49.1B, including $40.8B excluding contingents, with Cancer and Neurologic representing the most Q1 2026 M&A value.
Top Biopharma Therapeutics and Platforms M&A in Q1 2026
Gilead acquired Arcellx – February 2026
Gilead acquired Arcellx in February 2026 to expand its CAR-T and cell therapy leadership in multiple myeloma and broader oncology indications through the ARC-SparX platform and preregistration anitocabtagene autoleucel. Shareholders received $115 per share in cash, reflecting 79% and 68% premiums, plus a $5 CVR tied to cumulative net sales of at least $6B through 2029, representing an implied equity value of $8.2B. The transaction closed on April 28, 2026, with Arcellx integrated into Kite, a Gilead company.
Eli Lilly acquiring Centessa Pharmaceuticals – March 2026
Eli Lilly agreed to acquire Centessa Pharmaceuticals in March 2026 to strengthen its neurologic and sleep disorder portfolio with phase II cleminorexton (ORX-750), phase I ORX-142, and preclinical ORX-489. The deal includes approximately $6.3B upfront at $38 per share, reflecting premiums of approximately 37.8% and 40.5%, plus up to $1.5B in CVRs tied to FDA approval milestones.
Merck acquired Terns Pharmaceuticals – March 2026
Merck acquired Terns Pharmaceuticals in March 2026 to add TERN-701, a phase I/II therapy for Chronic Myeloid Leukemia (CML), and additional oncology assets. Shareholders received $53 per share in cash, representing 6%, 31%, and 42% premiums, for a total equity value of $6.7B. The acquisition closed on May 05, 2026.
Biogen acquiring Apellis Pharmaceuticals – March 2026
Biogen agreed to acquire Apellis Pharmaceuticals in March 2026 to expand its immunology, nephrology, rare disease, and ophthalmology portfolio with marketed complement-based therapies, including Empaveli and Syfovre. The assets generated $689M in revenue in 2025 and are expected to support EPS growth starting in 2027. The transaction values Apellis at $6.1B, including CVRs, with shareholders receiving $41 per share in cash plus up to $8 per share in milestone-based CVRs.
Novartis acquiring Pikavation Therapeutics from Synnovation Therapeutics – March 2026
Novartis agreed to acquire Pikavation Therapeutics from Synnovation Therapeutics in March 2026, adding pan-mutant selective PI3Kα inhibitor programs, including SNV-4818 for HR+/HER2 metastatic breast cancer and advanced solid tumors. The transaction includes $2B upfront and up to $1B in development, regulatory, and commercial milestones, strengthening Novartis’ oncology and small molecule portfolio.
Also check out Biopharma Therapeutics and Platforms R&D Partnerships – Q1 2026 Review
